Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 6:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 3,770 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Breast Cancer patient Clear all
Not listed Phase 2 Interventional

Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer

NCT01800422
View directory record Official record
Conditions
Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer
Interventions
telapristone acetate, placebo, therapeutic conventional surgery, laboratory biomarker analysis, questionnaire administration
Drug · Other · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 4, 2026, 6:50 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer

NCT02312622
View directory record Official record
Conditions
Stage IV Non-small Cell Lung Cancer (NSCLC), Recurrent Non-small Cell Lung Cancer (NSCLC), Extensive-stage Small Cell Lung Cancer (SCLC), Recurrent Small Cell Lung Cancer (SCLC), Tumors Metastatic to Brain, Metastatic Breast Cancer (mBC)
Interventions
Pegylated Irinotecan
Drug
Lead sponsor
Joel Neal
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 4, 2026, 6:50 PM EDT
Completed No phase listed Observational Results available

Ibrance Real World Insights

NCT03159195
View directory record Official record
Conditions
Malignant Neoplasm of Breast
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 4, 2026, 6:50 PM EDT
Completed No phase listed Observational

Combined Strength Training and Functional Endurance Exercise Regimen on Cancer -Related Fatigue and Physical Performance

NCT00421057
View directory record Official record
Conditions
Breast Cancer, Fatigue
Interventions
Combined Strength Training and Functional Endurance Exercise, Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
21 Years to 60 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Oct 4, 2026, 6:50 PM EDT
Active, not recruiting Phase 2 Interventional

Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer

NCT03598257
View directory record Official record
Conditions
Breast Inflammatory Carcinoma
Interventions
Biospecimen Collection, Olaparib, Radiation Therapy, Survey Administration
Procedure · Drug · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
214
States / cities
Anchorage, Alaska • Gilbert, Arizona • Tucson, Arizona + 174 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 4, 2026, 6:50 PM EDT
Withdrawn No phase listed Observational

Role of Hyaluronic Acid in Causing Cancer Stem Cell Growth in the Bones of Patients With Breast Cancer

NCT02331212
View directory record Official record
Conditions
Breast Carcinoma Metastatic to the Bone, Stage IV Breast Cancer
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
20 Years to 60 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 4, 2026, 6:50 PM EDT
Recruiting Phase 3 Interventional

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

NCT06058377
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Interventions
Biospecimen Collection, Cyclophosphamide, Doxorubicin, Durvalumab, Genetic Testing, Mammography, Paclitaxel, Quality-of-Life Assessment
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3,680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
555
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 427 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 4, 2026, 6:50 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer

NCT00821886
View directory record Official record
Conditions
Breast Cancer
Interventions
Ixabepilone, Trastuzumab, Carboplatin
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
12
States / cities
Fort Myers, Florida • Augusta, Georgia • Terre Haute, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced Oct 4, 2026, 6:50 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Chemotherapy With Whole Body Hyperthermia to Treat Resistant Breast, Endometrial, Cervical and Ovarian Cancers

NCT00178802
View directory record Official record
Conditions
Breast Neoplasms, Endometrial Neoplasms, Cervix Neoplasms, Ovarian Neoplasms
Interventions
thermochemotherapy (with 5-fluorouracil/interferon-a/liposomal doxorubicin)
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2010 · Synced Oct 4, 2026, 6:50 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer

NCT03414970
View directory record Official record
Conditions
Ductal Breast Carcinoma, Invasive Breast Carcinoma, Lobular Breast Carcinoma, Medullary Breast Carcinoma, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Tubular Breast Carcinoma
Interventions
Radiation Therapy, Questionnaire Administration, Quality-of-Life Assessment, Laboratory Biomarker Analysis, Hypofractionated Radiation Therapy
Radiation · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
898 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2035
U.S. locations
846
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 544 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 4, 2026, 6:50 PM EDT
Completed Phase 2 Interventional

Neoadjuvant Taxotere

NCT00206505
View directory record Official record
Conditions
Breast Cancer
Interventions
Taxotere
Drug
Lead sponsor
Baylor Breast Care Center
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2011 · Synced Oct 4, 2026, 6:50 PM EDT
Completed Not applicable Interventional

Diminish Chemotherapy Related Side Effects Through Patient Education

NCT04694794
View directory record Official record
Conditions
Chemotherapeutic Toxicity, Chemotherapeutic Agent Toxicity, Chemotherapy Effect
Interventions
Educational Brochure
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 4, 2026, 6:50 PM EDT
Not listed Not applicable Interventional

Prevention of Capsular Contracture Using Trental and Vitamin E

NCT01082003
View directory record Official record
Conditions
Capsular Contractures
Interventions
Trental
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Oct 4, 2026, 6:50 PM EDT
Completed Phase 2 Interventional

GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

NCT01480583
View directory record Official record
Conditions
Breast Cancer, Brain Metastases
Interventions
GRN1005, Trastuzumab, 18F-FLT
Drug
Lead sponsor
Angiochem Inc
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Harvey, Illinois • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 4, 2026, 6:50 PM EDT
Completed Phase 3 Interventional Results available

Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes

NCT01106040
View directory record Official record
Conditions
Breast Cancer, Melanoma
Interventions
Lymphoseek
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
8
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Oct 4, 2026, 6:50 PM EDT
Terminated Phase 1 Interventional Results available

A Study Of PF-06664178 In Patients With Advanced Solid Tumors

NCT02122146
View directory record Official record
Conditions
Neoplasms
Interventions
PF-06664178
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 4, 2026, 6:50 PM EDT
Completed Phase 2 Interventional Results available

GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer

NCT00068588
View directory record Official record
Conditions
Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
GTI-2040, capecitabine
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2014 · Synced Oct 4, 2026, 6:50 PM EDT
Withdrawn No phase listed Observational

Impact of Body Weight on Pharmacokinetic Analysis of Doxorubicin + Cyclophosphamide in Breast Cancer

NCT01542203
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 4, 2026, 6:50 PM EDT
Recruiting Phase 2 Interventional

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

NCT06099769
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Enzalutamide, Mifepristone, TPC
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
12
States / cities
Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 4, 2026, 6:50 PM EDT
Active, not recruiting Not applicable Interventional

Safety of Lower Scalp Cooling Temperature to Prevent Hair Loss From Chemotherapy in Breast Cancer Patients

NCT04180579
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Interventions
PAXMAN Scalp Cooler
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 4, 2026, 6:50 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread

NCT03098550
View directory record Official record
Conditions
Advanced Cancer
Interventions
Nivolumab, Daratumumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Long Beach, California • Aurora, Colorado • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 4, 2026, 6:50 PM EDT
Completed Phase 2 Interventional Results available

Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study

NCT05545150
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Bilateral Breast Carcinoma, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8
Interventions
Intraoperative Imaging, Lumpectomy
Procedure · Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Chicago, Illinois • Lexington, Kentucky • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 4, 2026, 6:50 PM EDT
Active, not recruiting Phase 1 Interventional

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

NCT03959891
View directory record Official record
Conditions
Breast Cancer
Interventions
Ipatasertib, Fulvestrant, Aromatase Inhibitor, Palbociclib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 4, 2026, 6:50 PM EDT
Recruiting Phase 2 Interventional

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

NCT07054190
View directory record Official record
Conditions
Breast Cancer
Interventions
Inavolisib, Ribociclib, Letrozole, Giredestrant
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Los Angeles, California • Orange, California • Germantown, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 4, 2026, 6:50 PM EDT